keyword
MENU ▼
Read by QxMD icon Read
search

synvisc

keyword
https://www.readbyqxmd.com/read/29026341/benefits-of-different-postoperative-treatments-in-patients-undergoing-knee-arthroscopic-debridement
#1
Cesáreo Trueba Vasavilbaso, Carlos David Rosas Bello, Erla Medina López, Maria Pilar Coronel Granado, José Mario Navarrete Álvarez, Cesáreo Angel Trueba Davalillo, Félix Isaac Gil Orbezo
PURPOSE: To assess the effectiveness of viscosupplementation or platelet-rich plasma (PRP), compared to standard care, for pain relief after knee arthroscopic debridement in patients with meniscal pathology and osteoarthritis (OA), under normal clinical practice conditions. PATIENTS AND METHODS: We conducted a prospective, randomized, evaluator-blind, pilot study. After arthroscopy, patients were randomized to receive 1) five injections of HA1 (Suprahyal(®)/Adant(®)); 2) four injections of HA2 (Orthovisc(®)); 3) three injections of HA3 (Synvisc(®)); 4) a single injection of PRP (GPS™ II); or 5) standard care (control)...
2017: Open Access Rheumatology: Research and Reviews
https://www.readbyqxmd.com/read/28841497/injectable-hydrogels-for-treatment-of-osteoarthritis-a-rheological-study
#2
Benjamin von Lospichl, Shabnam Hemmati-Sadeghi, Pradip Dey, Tilo Dehne, Rainer Haag, Michael Sittinger, Jochen Ringe, Michael Gradzielski
Osteoarthritis (OA) is a disabling condition especially in the elderly population. The current therapeutic approaches do not halt the OA progression or reverse joint damage. In order to overcome the problem of rapid clearance of hyaluronic acid (HA), a standard viscosupplement for OA, we investigated the rheological properties of a relatively non-degradable dendritic polyglycerol sulfate (dPGS) hydrogel to determine a suitable concentration for intra articular injections that mimics HA in terms of its viscoelastic and mechanical properties...
August 5, 2017: Colloids and Surfaces. B, Biointerfaces
https://www.readbyqxmd.com/read/28708631/development-of-systemic-inflammatory-polyarthritis-after-zygapophyseal-joint-injection-with-hylan-g-f-20-synvisc-one
#3
Denizen Kocak, Thiru Annaswamy, Sharon Chong, Rashmi Arora
Hylan G-F 20 (Synvisc-One) is a hyaluronic acid derivative used for viscosupplementation of synovial fluid in osteoarthritic joints. Injection of hylan G-F 20 is Federal Drug Administration approved for use in knee osteoarthritis and is generally well tolerated with few reported adverse effects, the most common being local pain or swelling. We present the case of a 72-year-old man with bilateral, diffuse, joint pain and swelling with elevated inflammatory markers suggestive of a systemic inflammatory polyarthropathy that developed acutely 2 days after lumbar zygapophyseal joint injection with hylan G-F 20...
July 13, 2017: American Journal of Physical Medicine & Rehabilitation
https://www.readbyqxmd.com/read/28545178/hylan-gf-20-viscosupplementation-in-the-treatment-of-symptomatic-osteoarthritis-of-the-knee-clinical-effect-survivorship-at-5-years
#4
Tarek Boutefnouchet, Guru Puranik, Esther Holmes, Karl M Bell
Purpose: Controversies remain surrounding the choice of hyaluronic acid products and patient selection. A study was conducted to report the long-term survivorship of intra-articular injection effect of high molecular weight hyaluronic preparation hylan GF-20 (Synvisc-One) for patients with symptomatic knee osteoarthritis. Materials and Methods: A retrospective observational analysis of a single therapeutic series was carried out. The analysis was conducted to determine therapeutic effect survivorship taking arthroplasty and any other surgical interventions as endpoint results...
June 1, 2017: Knee Surgery & related Research
https://www.readbyqxmd.com/read/28291178/comparison-of-single-intra-articular-injection-of-novel-hyaluronan-hya-joint-plus-with-synvisc-one-for-knee-osteoarthritis-a-randomized-controlled-double-blind-trial-of-efficacy-and-safety
#5
RANDOMIZED CONTROLLED TRIAL
Shu-Fen Sun, Chien-Wei Hsu, Huey-Shyan Lin, I-Hsiu Liou, Yin-Han Chen, Chia-Ling Hung
BACKGROUND: Viscosupplementation has been widely used for the treatment of knee osteoarthritis. Because we found no well-controlled trial comparing single-injection regimens of hyaluronan for knee osteoarthritis, we compared the efficacy and safety of a single intra-articular injection of a novel cross-linked hyaluronan (HYA-JOINT Plus) with a single injection of Synvisc-One in patients with knee osteoarthritis. METHODS: In a prospective, randomized, controlled, double-blind trial with a 6-month follow-up, 132 patients with knee osteoarthritis (Kellgren-Lawrence grade 2 or 3) were randomized to receive 1 intra-articular injection of 3 mL of HYA-JOINT Plus (20 mg/mL) (n = 66) or 6 mL of Synvisc-One (8 mg/mL) (n = 66)...
March 15, 2017: Journal of Bone and Joint Surgery. American Volume
https://www.readbyqxmd.com/read/27848271/improvement-in-condition-specific-and-generic-quality-of-life-outcomes-in-patients-with-knee-osteoarthritis-following-single-injection-synvisc-results-from-the-lobras-study
#6
MULTICENTER STUDY
P Kearey, A E Popple, J Warren, T Davis, N Bellamy
OBJECTIVE: To evaluate the effectiveness of viscosupplementation with single-injection hylan G-F20 (Synvisc-One) in knee osteoarthritis (OA), during routine clinical care, in a 52 week observational study. RESEARCH DESIGN AND METHODS: The LOBRAS study involved a 1 year long, multi-center, quasi-experimental, repeated measures, observational study. Consenting patients in Australia fulfilling inclusion/exclusion criteria under the care of a medical specialist in routine clinical practice were enrolled...
March 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/27673176/poster-426-comparisons-of-functional-pain-relief-after-bilateral-synvisc-injections-and-genicular-nerve-radiofrequency-ablations-a-case-report
#7
David Schanbacher, Michelle Poliak-Tunis, Michael J Suer
No abstract text is available yet for this article.
September 2016: PM & R: the Journal of Injury, Function, and Rehabilitation
https://www.readbyqxmd.com/read/27435213/hylan-g-f-20-versus-low-molecular-weight-hyaluronic-acids-for-knee-osteoarthritis-a-meta-analysis
#8
COMPARATIVE STUDY
Hongmou Zhao, Hongliang Liu, Xiaojun Liang, Yi Li, Junhu Wang, Cheng Liu
BACKGROUND: Hyaluronic acid injection has been reported to decrease pain compared with baseline levels in knee joint osteoarthritis. Hylan G-F 20 is distinguished from the other products by its chemical structure and relatively higher molecular weight. Many trials have compared hylan G-F 20 and low molecular weight hyaluronic acids (LMWHAs); however, their relative efficacy and safety are still debated. OBJECTIVE: The aim was to compare the effectiveness and safety of intra-articular injection of hylan G-F 20 and LMWHA in the treatment of knee joint osteoarthritis...
October 2016: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/27403194/clinical-and-cost-outcomes-from-different-hyaluronic-acid-treatments-in-patients-with-knee-osteoarthritis-evidence-from-a-us-health-plan-claims-database
#9
Vinod Dasa, Mitch DeKoven, Kainan Sun, Allan Scott, Sooyeol Lim
BACKGROUND: Intra-articular injection of hyaluronic acid (HA) for knee osteoarthritis (OA) effectively reduces pain and delays total knee replacement (TKR) surgery; however, little is known about relative differences in clinical and cost outcomes among different HA products. OBJECTIVE: To compare disease-specific costs and risk of TKR among patients receiving different HA treatments in a commercially insured cohort of patients with knee OA in the USA. METHOD: Retrospective analyses using IMS Health's PharMetrics Plus Health Plan Claims Database were conducted by identifying knee OA patients with claims indicating initiation of HA treatment at an 'index date' during the selection period (2007-2010)...
2016: Drugs in Context
https://www.readbyqxmd.com/read/27146676/cost-effectiveness-of-different-forms-of-intra-articular-injections-for-the-treatment-of-osteoarthritis-of-the-knee
#10
Jeffrey Rosen, Parag Sancheti, Anke Fierlinger, Faizan Niazi, Herman Johal, Asheesh Bedi
INTRODUCTION: Osteoarthritis (OA), as one of the leading causes of disability, decreases the quality of life for those suffering from the disease and creates a substantial financial burden. Intra-articular hyaluronic acid (HA) can provide relief from the symptoms of OA and multiple HA products are prescribed. The purpose of this study is to examine the single payer cost-effectiveness of various HA products in the treatment of knee OA. METHODS: A single payer economic evaluation was conducted comparing Synvisc(®) (Sanofi, USA), Durolane(®) (Bioventus, USA), Hyalgan(®) (Fidia Pharma Inc...
June 2016: Advances in Therapy
https://www.readbyqxmd.com/read/27071650/characterization-of-viscosupplementation-formulations-using-chemical-exchange-saturation-transfer-viscocest
#11
Mohammad Haris, Anup Singh, Sanjana Reddy, Puneet Bagga, J Bruce Kneeland, Fotios P Tjoumakaris, Hari Hariharan, Francesco M Marincola, Ravinder Reddy
BACKGROUND: Osteoarthritis (OA) is characterized by progressive loss of cartilage in joints, and is a major cause of pain and disability, and imposes significant health care expense. New therapies are being developed to treat the symptomatic effect of OA, one of which is intra-articular injection of viscosupplementations of different forms of hyaluronic acid (HA). The current study evaluates the chemical exchange saturation transfer (CEST) effect from two popular viscosupplementations [Hylan gf-20 (Synvisc) and hyaluronan (Orthovisc)] by targeting the exchangeable hydroxyl protons present on these molecules (ViscoCEST)...
April 12, 2016: Journal of Translational Medicine
https://www.readbyqxmd.com/read/26257790/alterations-in-the-secretome-of-clinically-relevant-preparations-of-adipose-derived-mesenchymal-stem-cells-cocultured-with-hyaluronan
#12
Peter Succar, Edmond J Breen, Donald Kuah, Benjamin R Herbert
Osteoarthritis (OA) can be a debilitating degenerative disease and is the most common form of arthritic disease. There is a general consensus that current nonsurgical therapies are insufficient for younger OA sufferers who are not candidates for knee arthroplasties. Adipose-derived mesenchymal stem cells (MSCs) therapy for the treatment of OA can slow disease progression and lead to neocartilage formation. The mechanism of action is secretion driven. Current clinical preparations from adipose tissue for the treatment of OA include autologous stromal vascular fraction (SVF), SVF plus mature adipocytes, and culture-purified MSCs...
2015: Stem Cells International
https://www.readbyqxmd.com/read/25887932/safety-and-performance-of-hydros-and-hydros-ta-for-knee-osteoarthritis-a-prospective-multicenter-randomized-double-blind-feasibility-trial
#13
RANDOMIZED CONTROLLED TRIAL
Robert J Petrella, Pieter J Emans, Julia Alleyne, Frank Dellaert, Dawn P Gill, Marcee Maroney
BACKGROUND: Studies have evaluated the concomitant use of hyaluronan (HA) with steroids, anti-inflammatory drugs and analgesic agents in an attempt to magnify the extent and duration of pain relief due to knee osteoarthritis. To date there has not been an intra-articular combination therapy available for relief of knee osteoarthritis symptoms--one that combines the fast acting onset of symptom relief provided by a corticosteroid with the long-lasting symptom relief provided by HA in a single injection...
March 18, 2015: BMC Musculoskeletal Disorders
https://www.readbyqxmd.com/read/25782964/safety-and-performance-of-hydros-and-hydros-ta-for-knee-osteoarthritis-a-prospective-multicenter-randomized-double-blind-feasibility-trial
#14
Robert J Petrella, Pieter J Emans, Julia Alleyne, Frank Dellaert, Dawn P Gill, Marcee Maroney
BACKGROUND: Studies have evaluated the concomitant use of hyaluronan (HA) with steroids, anti-inflammatory drugs and analgesic agents in an attempt to magnify the extent and duration of pain relief due to knee osteoarthritis. To date there has not been an intra-articular combination therapy available for relief of knee osteoarthritis symptoms - one that combines the fast acting onset of symptom relief provided by a corticosteroid with the long-lasting symptom relief provided by HA in a single injection...
December 2015: BMC Musculoskeletal Disorders
https://www.readbyqxmd.com/read/25153804/biocompatibility-of-cross-linked-hyaluronate-gel-200-for-the-treatment-of-knee-osteoarthritis
#15
M Ishikawa, K Yoshioka, K Urano, Y Tanaka, T Hatanaka, A Nii
OBJECTIVE: To compare the biocompatibility and immunogenicity of two intra-articular hyaluronan formulations, Gel-200 (Gel-One(®)) and hylan G-F 20 (Synvisc(®) series). EXPERIMENTAL DESIGN: A comparison of the biocompatibility of Gel-200 and hylan G-F 20 was made using a rat subcutaneous air pouch model and the knee joint of normal rabbits. Immunogenicity was evaluated using a homologous passive cutaneous anaphylaxis (PCA) assay in guinea pigs. RESULTS: In the air pouch model in rats, characteristic fibrous belts formed in the subcutaneous tissue...
November 2014: Osteoarthritis and Cartilage
https://www.readbyqxmd.com/read/24500880/immunological-response-to-bolus-versus-multiple-injections-of-hylan-g-f-20-synvisc-in-a-murine-biocompatibility-model
#16
David C Markel, Nancy M Jackson, Amanda O Esquivel, Weiping Ren, Jeffrey C Flynn
Local tissue reactivity to intra-articular injections of hyaluronic acid hylan G-F 20 (Synvisc) has been described. We used a murine biocompatibility model to study the inflammatory response to Synvisc after a single bolus injection versus the traditional three shot series of injections. Air pouches were established subcutaneously in BALB/c mice, which were injected with phosphate-buffered saline (PBS), 5 mg ultra-high molecular weight polyethylene particles (to simulate synthetic joint wear debris, positive control), 0...
October 2014: Journal of Biomedical Materials Research. Part B, Applied Biomaterials
https://www.readbyqxmd.com/read/24487346/changes-of-synovial-fluid-protein-concentrations-in-supra-patellar-bursitis-patients-after-the-injection-of-different-molecular-weights-of-hyaluronic-acid
#17
Carl P C Chen, Chih Chin Hsu, Yu-Cheng Pei, Ruo Li Chen, Shaobo Zhou, Hsuan-Chen Shen, Shih-Cherng Lin, Wen Chung Tsai
Knee pain is commonly seen in orthopedic and rehabilitation outpatient clinical settings, and in the aging population. Bursitis of the knee joint, especially when the volume of the synovial fluid is large enough, can compress and distend the nearby soft tissues, causing pain in the knee joint. Out of all the bursae surrounding the knee joint, supra-patellar bursitis is most often associated with knee pain. Treatment strategies in managing supra-patellar bursitis include the aspiration of joint synovial fluid and then followed by steroid injection into the bursa...
April 2014: Experimental Gerontology
https://www.readbyqxmd.com/read/24035888/effect-of-addition-of-hyaluronic-acids-on-the-osteoconductivity-and-biodegradability-of-synthetic-octacalcium-phosphate
#18
Kentaro Suzuki, Takahisa Anada, Tatsuya Miyazaki, Naohisa Miyatake, Yoshitomo Honda, Koshi N Kishimoto, Masami Hosaka, Hideki Imaizumi, Eiji Itoi, Osamu Suzuki
The present study was designed to investigate whether three sodium hyaluronic acid (HyA) medical products, Artz(®), Suvenyl(®) and a chemically modified derivative of sodium HyA Synvisc(®), can be used as suitable vehicles for an osteoconductive octacalcium phosphate (OCP). OCP granules (300-500 μm diameter) were mixed with these sodium HyAs with molecular weights of 90 × 10(4) (Artz(®)), 190 × 10(4) (Suvenyl(®)) and 600 × 10(4) (Synvisc(®)) (referred to as HyA90, HyA190 and HyA600, respectively)...
January 2014: Acta Biomaterialia
https://www.readbyqxmd.com/read/23873318/no-conclusive-evidence-that-histologically-found-granulomas-and-acute-local-reactions-following-hylan-g-f-20-injections-are-related-or-have-clinical-significance
#19
David D Waddell, Alan Beyer, Terry L Thompson, Jennifer Morawiak, Clare Elkins, Andrew Rosenberg, Andrew Spitzer
Osteoarthritic (OA) knee pain can be successfully treated with hylan G-F 20 (Synvisc, Sanofi Biosurgery, Cambridge, MA) with few local adverse events. However, a few studies have identified hyaluronate positive (HA+) granulomas in the synovial tissue of patients treated with hylan G-F 20 raising the question of their relationship and clinical significance. To understand the potential relationship of HA+ granulomas with the occurrence of acute local reactions (ALRs), we evaluated the synovial tissue of OA patients undergoing total knee replacement that had previously been treated with hylan G-F 20 (n = 101) or had not been treated (n = 20)...
April 2014: Journal of Knee Surgery
https://www.readbyqxmd.com/read/23514620/hyaluronic-acid-nanoparticles-titrate-the-viscoelastic-properties-of-viscosupplements
#20
Amir Fakhari, Quang Phan, Santosh V Thakkar, C Russell Middaugh, Cory Berkland
Hyaluronic acid (HA) is a glycosaminoglycan with diverse biomedical applications including viscosupplementation of synovial fluid for the treatment osteoarthritis. Current HA viscosupplements such as Synvisc, Orthovisc, and Hyalgan have shown positive effects of reducing pain and improving joint function. The therapeutic efficacy, however, is highly transient, and these viscous fluids suffer from poor injectability. HA nanoparticles were found to modify the rheological properties of a model of the HA viscosupplement Orthovisc...
April 30, 2013: Langmuir: the ACS Journal of Surfaces and Colloids
keyword
keyword
57254
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"